SCHEMBL5595029

SCHEMBL5595029

CCOP(=O)(COS(C)(=O)=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
PPARD Q03181 2/20 0.41
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MMP9 P14780 1/20 0.37
ALOX15 P16050 1/20 0.37
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ACHE P22303 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456446 0.84 TSHR (0.50) TSHRPPARDTP53TDP1ACHE
SCHEMBL8717549 0.82 TSHR (0.40) TSHRPPARDKDM4EUSP2ALDH1A1
SCHEMBL10894245 0.80 TSHR (0.39) TSHRPPARDKDM4EUSP2ALDH1A1
SCHEMBL16160738 0.80 TSHR (0.46) TSHRPPARDTP53TDP1CA1
SCHEMBL11688723 0.78 PPARD (0.48) TSHRPPARDKDM4EUSP2ALDH1A1
SCHEMBL10896547 0.78 TSHR (0.39) TSHRPPARDKDM4EUSP2ALDH1A1
SCHEMBL8722320 0.78 TSHR (0.50) TSHRPPARDKDM4EUSP2ALDH1A1
SCHEMBL4685763 0.76 USP2 (0.40) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL282279 0.75 TSHR (0.41) TSHRPPARDALDH1A1TP53TDP1
SCHEMBL15012040 0.74 TSHR (0.40) TSHRPPARDKDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4428980-A1 ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME Soulbrain Co., Ltd. (KR) 2024-09-11 EP disclosed
WO-2023080633-A1 ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME 솔브레인 주식회사 2023-05-11 WO disclosed
CN-107709288-A Phosphamide derivative and preparation method and application thereof 四川海思科制药有限公司 2018-02-16 CN disclosed
WO-2017133517-A1 PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF 四川海思科制药有限公司 2017-08-10 WO disclosed
WO-2017133517-A1 PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF 四川海思科制药有限公司 2017-08-10 WO disclosed
US-9642369-B2 Phosphorus functional antimicrobial coatings for metal surfaces NANO SAFE COATINGS INCORPORATED (US) 2017-05-09 US disclosed
US-9642369-B2 Phosphorus functional antimicrobial coatings for metal surfaces NANO SAFE COATINGS INCORPORATED (US) 2017-05-09 US disclosed
EP-2573854-B1 NON-AQUEOUS ELECTROLYTE SOLUTION CONTAINING SILYL ESTER GROUP-CONTAINING PHOSPHONIC ACID DERIVATIVE, AND LITHIUM SECONDARY BATTERY MITSUI CHEMICALS INC (JP) 2017-01-04 EP disclosed
US-20160374345-A1 PHOSPHONATE FUNCTIONAL ANTIMICROBIAL COATINGS FOR METAL SURFACES NANO SAFE COATINGS, LLC 2016-12-29 US disclosed
US-20160066579-A1 PHOSPHORUS FUNCTIONAL ANTIMICROBIAL COATINGS FOR METAL SURFACES BIOSHIELD TECHNOLOGIES CANADA LIMITED (CA) 2016-03-10 US disclosed
EP-1711617-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-10-18 EP disclosed
WO-2005064008-A9 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES INC (US) 2006-09-28 WO disclosed
EP-1620445-A2 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-02-01 EP disclosed
EP-1575486-A2 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-09-21 EP disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
EP-1501841-A2 NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2005-02-02 EP disclosed
WO-2004096818-A2 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2004-11-11 WO disclosed
WO-2003090691-A2 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
WO-2003091264-A2 NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
EP-0317881-A2 Pyridyl- and pyrazinyl compounds, process for their preparation, composition containing them and their use as fungicides HOECHST AKTIENGESELLSCHAFT (DE) 1989-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160066579-A1 PHOSPHORUS FUNCTIONAL ANTIMICROBIAL COATINGS FOR METAL SURFACES PHOSPHO1, FHIT, IPMK TSHR 3462/4885PPARD 1462/4885KDM4E 1769/4885
US-20160374345-A1 PHOSPHONATE FUNCTIONAL ANTIMICROBIAL COATINGS FOR METAL SURFACES PHOSPHO1, FHIT, CDC14B TSHR 3981/4885PPARD 1858/4885KDM4E 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.